Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery

Chen Chen¹,²†, Wei Yi³†, Zhi-fan Zeng¹,², Qiao-xuan Wang¹,², Wu Jiang²,⁴, Yuan-hong Gao¹,²* and Hui Chang¹,²*

Abstract

Background: The ratio of serum apolipoprotein B (apoB) to apolipoprotein A-I (apoA-I) had been reported as a prognostic factor in colorectal cancer. This retrospective study aimed to assess the implication of apoB-to-apoA-I ratio in predicting liver metastasis from rectal cancer (RC).

Methods: The clinical data of 599 locally advanced RC patients treated with chemoradiotherapy followed by surgery were reviewed. Serum apoA-I, apoB and apoB-to-apoA-I ratio were analyzed for their correlation with the liver-metastasis-free, other-metastasis-free and overall survivals, together with the pretreatment and postsurgical pathoclinical features of the patients. Univariate and multivariate survival analyses were realized through the Kaplan-Meier approach and Cox model, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for independent predictors.

Results: Carbohydrate antigen 19 − 9 ≥ 26.3 U/ml, apoB-to-apoA-I ratio ≥ 0.63, tumor regression grade 5 − 3, pT4 and pN+ stage emerged as independent predictors of poorer liver-metastasis-free survival. The hazard ratios were 1.656 (95% CI, 1.094–2.506), 1.919 (95% CI, 1.174–3.145), 1.686 (95% CI, 1.053–2.703), 1.890 (95% CI, 1.110–3.226) and 2.012 (95% CI, 1.314–2.077), respectively. Except apoB-to-apoA-I ratio, the other 4 factors were also independent predictors of poorer other-metastasis-free and overall survivals. And the independent predictors of poorer overall survival also included age ≥ 67 years old, distance to anal verge < 5 cm.

Conclusions: Serum apoB-to-apoA-I ratio could be used as a biomarker for prediction of liver metastasis risk in locally advanced RC.

Keywords: Rectal cancer, Liver metastasis, Apolipoprotein, Survival

Background

Currently, locally advanced rectal cancer (RC) is primarily treated by chemoradiotherapy plus surgery [1]. Despite an ideal local control, the 5-year distant metastasis rate remains to be more than 20% [2]. Based on published studies, liver metastasis (LM) is the most common type of distant failure and leads to a median survival
time of merely 19.7 months. Yet, the figure could rise to 64.5 months when the LM lesion is resectable [3, 4]. For improving patient survival, it is important to predict LM or diagnose it at a resectable size.

Until now, few factors are identified for specific prediction of LM from RC. In a study by Chen et al., commonly used anatomical prognosticators of RC were analyzed for their association with LM. Of those, only distal tumor appeared to predict a higher LM risk [5]. Serum biomarkers could indirectly reflect tumor-host interactions and be considered as candidate predictors of LM. Meltzer et al. reported that elevated circulating sCD40 level correlated independently with a shorter time to LM [6]. But the analysis procedure of sCD40 was complicated and needed advanced examination conditions. Thus, there is a need to find predictors of LM from routinely tested indices.

Apolipoprotein is a family of serum proteins which facilitate lipid transportation and are discovered recently to participate in cancer metabolism and immunity [7]. Some apolipoproteins have exhibited their prognostic values in colorectal cancer. The serum level of apolipoprotein A-I (apoAI) and apolipoprotein B (apoB) were reported as positive and negative predictors of patient survival, respectively [8–10]. Yang et al. further combined these 2 indices into apoB-to-apoAI ratio and achieved improved prediction efficiency [11]. In the literature, the values of apoAI and apoB in predicting LM of RC are still unknown.

In this study, we reviewed a large cohort of 599 patients diagnosed with locally advanced RC and treated with a standard treatment composed by neoadjuvant chemoradiotherapy (NACRT) and radical surgery. Patho-clinical factors, together with serum apoAI, apoB and apoB-to-apoAI ratio, were then analyzed on their association with patients’ liver-metastasis-free survival (LMFS). Cutoff values with the best prediction efficiency were established for the apolipoprotein-related indices.

**Methods**

**Patient cohort**

Clinical data of locally advanced RC (pretreatment clinical stage T3-4N0M0 and cT1-4N1-2M0) patients were extracted from the medical record database of the Sun Yat-sen University Cancer Center. The cases would be eligible for this study if they met the following criteria: (i) pathological diagnosis was made from Jan. 1st 2007 to Apr. 30th 2016; (ii) age at diagnosis was from 18 to 75 years old; (iii) Karnofsky performance score ≥ 80; (iv) treatment procedure consisted of NACRT and radical (R0) resection. And the cases would be excluded if they had: (i) any other prior malignancies; (ii) history of excessive drinking or drug abuse; (iii) treatment with monoclonal antibody; (iv) regular use of lipid-modulating agents, such as fibrates, niacins and statins; (v) distant metastasis during treatment.

**Diagnostic and staging work-up**

Initial pathological diagnosis of rectal cancer was obtained through biopsy under rectoscope. Local extension and lymph node involvement at diagnosis were evaluated through pelvic magnetic resonance imaging (MRI) and endoscopic ultrasonography. Metastasis in distant organs such as liver were detected through thoracoabdominal computed tomography (CT) and further confirmed through positron emission tomography, if necessary. Specimens from radical resection were sent for pathologic examinations to assess tumor infiltration and differentiation, numbers of examined and involved lymph nodes, and tumor regression grade (TRG) after NACRT. The stages of each patient before treatment and after surgery were both made according to the TNM classification of the Union for International Cancer Control-American Joint Cancer Committee. The TRG criteria used in our hospital was the Mandar’s 5-tier grading system.

**Detection of serum biomarkers**

Before treatment, the serum levels of apoAI and apoB were detected via the LABOSPECT 008 biochemistry system (Hitachi, Tokyo, Japan). And the serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19–9 (CA19-9) were detected via the E170 electrochemiluminescent immunoassay system (Roche Diagnostics, Tokyo, Japan). All detection were in accordance with the manufacturers’ instructions.

**Chemoradiotherapy and surgery**

Radiotherapy was administered by using a three-dimensional conformal or intensified modulated radiation technique. The irradiation target of each patient was delineated according to the guidelines of the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed doses for macroscopic tumor (containing primary lesion and metastatic lymph nodes) and high-risk (containing pararectal, presacral, obturator, internal and common iliac) lymphatic drainage regions were 50 and 46 Gy, respectively. The patients were irradiated with a linear accelerator delivering an 8-MV photon beam, for totally 25 fractions (1 fraction per day, 5 days per week). Chemotherapy was administered every 3 weeks, with a regimen consisting of oxaliplatin 130 mg/m² on Day 1, plus capecitabine 1000 mg/m² twice daily on Days 1–14. Totally 8 cycles of chemotherapy was prescribed, including 2–4 and 4–6 cycles in the neoadjuvant and adjuvant phases, respectively. Radical surgery was scheduled 8–12 weeks after
radiotherapy, in accordance with the standard of total mesorectal excision.

Follow-up
In the first 3 years after treatment, follow-up was performed every 3–6 months through outpatient interview. After the third year, follow-up was performed every 6–12 months, through outpatient interview or telephone. At each outpatient interview, the patients received a complete physical examination, thoraco-abdominal CT, pelvic MRI, serum CEA and CA19-9 tests. Rectoscope and whole-body bone scan were arranged annually. Follow-up lasted until death from rectal cancer (confirmed by death certificates) or Apr. 30th 2021, whichever came first.

Endpoint definition
The primary endpoint in this study was LMFS, which was defined as the percentage of the patients surviving without LM over a given time period from pathologic diagnosis. The secondary endpoints included overall survival (OS) and other-metastasis-free survival (OMFS). The OS was defined as the percentage of the patients surviving over a given time period from diagnosis. And the OMFS was defined as the percentage of the patients who survived without metastasis other than LM, over a given time period from diagnosis.

Variables and cutoff values
The variables for survival analysis included age, gender (male vs. female), tumor differentiation (poorly vs. moderately-well), distance to anal verge, pretreatment T stage (cT4 vs. cT3-1), pretreatment N stage (cN+ vs. cN0), CEA, CA19-9, apoAI, apoB, apoB-to-apoAI ratio, active viral hepatitis (yes vs. no), TRG (5–3 s. 2–1), postsurgical T stage (pT4 vs. pT3-0), postsurgical N stage (pN+ vs. pN0), and total chemotherapy cycle. The cutoff values of distance to anal verge was 5 (<5 vs. ≥5) cm, which was the cutoff value for distal and proximal RC in the guidelines of the National Comprehensive Cancer Network. The cutoff value of chemotherapy cycle was 8 (<8 vs. ≥8), which was proved by our previous work to influence distant metastasis rate of RC [12]. The best cutoff values of the rest continuous variables were the values achieving the maximum Youden indices in receiver operating characteristic (ROC) analysis.

Survival analysis
The candidate predictors of the LMFS, OM and OMFS were first screened through univariate analysis based on the Kaplan-Meier approach. Survival difference between the patients grouped by each variable was tested by the log-rank test. The variables with significant difference were then entered into multivariate analysis based on the Cox proportional hazards model. The hazard ratio (HR) and 95% confidence interval (CI) was calculated for each variable. A variable was considered as independent predictors if it had a HR significantly different from the reference HR.

All the statistical analyses of this study were completed through the IBM SPSS Statistics 23.0 (IBM Corp., Armonk, NY, USA). The analysis process was summarized as Fig. 1. A difference with a two-sided P value of <0.05 was regarded to have statistically significance.

Results
Baseline pathoclinical profiles
From Jan. 2007 to Apr. 2016, there were a total of 1409 consecutive patients diagnosed with untreated locally advanced RC in our hospital. Among them, 810 cases were excluded for: (i) treatment without radiotherapy (N=463); (ii) radiotherapy after surgery (N=201); (iii) age >75 years old (N=20); (iv) prior malignancies (N=36); (v) incomplete NACRT (N=29); (vi) monoclonal antibody therapy (N=28); (vii) non-R0 resection (N=17); (viii) distant metastasis during treatment (N=16). Then 599 cases receiving NACRT followed by R0 resection were eligible for subsequent analyses. The baseline clinical characteristics of the study cohort were summarized in Table 1. Continuous and categorical data are presented as median (range) and number (percentage), respectively.

Cutoff values of variables
The study cohort was followed up for a median time of 71 (range, 10–162) months. The number of patients lost to follow-up was 31 (5.2%). Death happened in 130 patients (21.7%), including 129 (21.5%) RC-related deaths. Recurrence happened in 33 (5.5%) patients. And distant metastases happened in 167 (27.9%) patients, including 129 (21.5%) RC-related deaths. Recurrence HR.

Death prediction were 67 (≥67 vs. <67) years old, 1.22 (<1.22 vs. ≥1.22) g/L, 1.06 (≥1.06 vs. <1.06) g/L, 0.63 (≥0.63 vs. <0.63), 6.1 (≥6.1 vs. <6.1) ng/ml, and 26.3 (≥26.3 vs. <26.3) U/ml.

Patient survival
In univariate analysis, the patients with CA19-9 ≥26.3 U/ml, apoB-to-apoAI ratio ≥0.63, TRG 5–3, pT4 and pN+ stage appeared to have a poorer 5-year LMFS (P values were 0.001, 0.016, < 0.001, < 0.001 and <0.001;
The patients with age ≥ 67 years old, distance to anal verge < 5 cm, cT4 stage, CEA ≥ 6.1 ng/ml, CA19-9 ≥ 26.3 U/ml, TRG 5−3, pT4 and pN+ stage had a poorer 5-year OS (P values were 0.004, 0.018, 0.026, 0.032, < 0.001, < 0.001, < 0.001 and < 0.001; Figure S1), respectively. And the patients with CEA ≥ 6.1 ng/ml, CA19-9 ≥ 26.3 U/ml, TRG 5−3, pT4 and pN+ stage had a poorer 5-year OMFS (P values were < 0.001, < 0.001, < 0.001, 0.008 and < 0.001; Figure S2), respectively.

Next, multivariate analyses were performed to evaluate the predictive independence of the possible predictors. As a result, CA19-9, apoB-to-apoAI ratio, TRG, pathologic T and N stages maintained to be independent predictors of LMFS (P values were 0.017, 0.009, 0.030, 0.019 and 0.001; Fig. 3 A), respectively. The adjusted HR for LMFS in the patients with apoB-to-apoAI ratio ≥ 0.63 was 1.656 (95% CI, 1.094–2.506), 1.919 (95% CI, 1.174–3.145), 1.686 (95% CI, 1.053–2.703), 1.890 (95% CI, 1.110–3.226) and 2.012 (95% CI, 1.314–2.077), respectively. The CA19-9, TRG, and pathologic T and N stages were all balanced between the patients with different apoB-to-apoAI ratios. It further supported apoB-to-apoAI ratio as an independent predictor of LM.

Discussion
LM is frequently seen in locally advanced RC. In this study, 17.4% of the patients were finally observed to undergo LM, after a median follow-up time of nearly 6 years. This figure was similar to prior studies [6, 13]. To select predictors of LM, a series of pathoclinical factors were analyzed for their association with LM risk. The results indicated that CA19-9 ≥ 26.3 U/ml, apoB-to-apoAI ratio ≥ 0.63, TRG 5−3, pT4 and pN+ stage correlated independently with a decreased 5-year LMFS. The HRs were 1.656 (95% CI, 1.094–2.506), 1.919 (95% CI, 1.174–3.145), 1.686 (95% CI, 1.053–2.703), 1.890 (95% CI, 1.110–3.226) and 2.012 (95% CI, 1.314–2.077), respectively. The CA19-9, TRG, and pathologic T and N stages were all balanced between the patients with different apoB-to-apoAI ratios. It further supported apoB-to-apoAI ratio as an independent predictor of LM.
Also, the same factors were analyzed for their association with risk of metastases to other organs. Of those, CA19-9 $\geq 26.3$ U/ml, TRG 5–3, pT4 and pN+ stages correlated independently with a decreased 5-year OMFS. The HRs were 1.631 (95% CI, 1.079–2.469), 1.848 (95% CI, 1.155–2.959), 1.764 (95% CI, 1.038–2.994) and 1.848 (95% CI, 1.209–2.825), respectively. But apoB-to-apoAI exhibited no correlation with patients’ OMFS. Namely, apoB-to-apoAI was a factor specifically predicting LM from RC. Since pathologic TNM stage and TRG could only be determined after surgery, apoB-to-apoAI had a superiority in helping clinicians to evaluate individual risk of LM at an early time. Additionally, all the predictors of LMFS also emerged as independent predictors of OS, except apoB-to-apoAI. The possible reason was that metastases in liver and other organs both contributed to cancer-related death.

Mounting evidences connect lipid metabolism to biological behaviors of cancer cells, including proliferation, apoptosis, invasion and migration. A key mechanism is the lipid raft comprising of cholesterol and sphingolipid on cell membrane. This microdomain functions as a signal transduction platform and selectively recruits receptors, adhesion molecules and signaling molecules. ApoAI and apoB are both cholesterol transporters in blood circulation but have different destinations. ApoAI transports excess cholesterol to liver cells where cholesterol is transformed into bile acids. Oppositely, apoB is responsible for cholesterol accumulation in peripheral tissue and tumor cells [7, 14, 15]. It confers these two apolipoproteins different roles in regulating cancer pathophysiology. ApoAI is now believed to have anti-tumor activities. Laboratory studies indicated that apoAI exerted inhibitory effects on growth and metastasis of cancer cells, both in vitro and in vivo. Besides, it could modulate tumor microenvironment, including decrease of immune escape-related cells (myeloid-derived suppressor cells, etc.), increase of tumor killer cells (CD8+ T-lymphocytes, etc.), induction of macrophage M2/M1 phenotype shift, and suppression of VEGF-mediated angiogenesis [16]. In clinical studies, low level of serum apoAI was associated with poor OS of some solid tumors, including lung, renal, and esophageal carcinoma [17–19]. One previous study by us showed that low serum apoAI predict a poor OS as well as increased distant metastases in nasopharyngeal carcinoma [20]. Though relative reports were not as many as apoAI, apoB is considered to have tumor-promoting effects. Liu et al. found a correlation between polymorphisms of apoB gene and risk of breast cancer [21]. Cédó et al. further found that apoB stimulated growth of estrogen receptor-positive breast cancer cells, via transporting 27-hydroxycholesterol [22].

Recently, the prognostic implications of serum apoAI and apoB in colorectal cancer have been gradually

### Table 1 Pretreatment pathoclinical characteristics of the 599 patients eligible for this study

| Characteristic                      | Value                      |
|------------------------------------|----------------------------|
| Age at diagnosis (years old)       | 56 (18–75)                 |
| No. of patients by gender          |                            |
| Male                               | 396 (66.1%)                |
| Female                             | 203 (33.9%)                |
| No. of patients by tumor differentiation |                  |
| Low                                | 63 (10.5%)                 |
| Moderate                           | 458 (76.5%)                |
| High                               | 78 (13.0%)                 |
| Distance to anal verge (cm)        | 5.0 (1.0–15.0)             |
| No. of patients by clinical T stage|                            |
| cT4b                               | 26 (4.3%)                  |
| cT4a                               | 249 (41.6%)                |
| cT3                                | 314 (52.4%)                |
| cT2                                | 10 (1.7%)                  |
| cT1                                | 0 (0.0%)                   |
| No. of patients by clinical N stage|                            |
| cN2                                | 213 (35.6%)                |
| cN1                                | 280 (46.7%)                |
| cN0                                | 106 (17.7%)                |
| CEA (ng/ml)                        | 4.2 (0.0–392.0)            |
| CA19-9 (U/ml)                      | 13.8 (0.0–985.6)           |
| ApoAI (g/L)                        | 1.19 (0.51–2.05)           |
| ApoB (g/L)                         | 0.90 (0.39–1.78)           |
| ApoB-to-apoAI ratio                | 0.75 (0.23–1.92)           |
| No. of patients by radiotherapy technique |                        |
| 3DCRT                              | 163 (27.2%)                |
| IMRT                               | 436 (72.8%)                |
| No. of patients by TRG             |                            |
| 5                                  | 16 (2.7%)                  |
| 4                                  | 107 (17.8%)                |
| 3                                  | 202 (33.7%)                |
| 2                                  | 137 (22.9%)                |
| 1                                  | 137 (22.9%)                |
| No. of patients by pathological T stage |                      |
| pT4b                               | 13 (2.2%)                  |
| pT4a                               | 36 (6.0%)                  |
| pT3                                | 240 (40.1%)                |
| pT2                                | 135 (22.5%)                |
| pT1                                | 24 (4.0%)                  |
| pT0                                | 151 (25.2%)                |
| No. of patients by pathologic N stage |                      |
| pN2                                | 26 (4.3%)                  |
| pN1                                | 103 (17.2%)                |
| pN0                                | 470 (78.5%)                |
| Chemotherapy cycle                 | 7 (4–10)                   |
| No. of patients by active viral hepatitis |              |
| Yes                                | 82 (13.7%)                 |
| No                                | 517 (86.3%)                |

*Abbreviations: CEA carcinoembryonic antigen; CA19-9 carbohydrate antigen 19–9; apoAI apolipoprotein A-I; apoB apolipoprotein B; 3DCRT three-dimensional conformal radiation therapy; IMRT, intensified modulated radiation therapy; TRG, tumor regression grade*
revealed. Ye et al. and Chen et al. reported that serum apoAI and apoB as positive and negative predictors of overall and progression-free survivals in colorectal cancer, respectively [9, 10]. Another previous study by us showed that low serum apoAI led to a bad NACRT-response in RC [23]. Some studies combined apoAI and apoB into a more powerful index, apoB-to-apoAI ratio. Sirniö et al. and Yang et al. found high apoB-to-apoAI ratio as a risk factor of cancer-related death, in both non-metastatic and metastatic colorectal cancer [11, 24]. As is known, apoAI and apoB are mainly synthesized and released by liver cells [14]. Combining their synthesis site and regulatory functions in cancer, it is not hard to understand their abilities in predicting LM.

Lipid-modulating drugs have already been put into clinical application for a long time. Some of them are able to affect serum levels of apolipoproteins. For example, statins and niacins could elevate serum apoAI level [25, 26]. Fibrate could increase serum apoAI and decrease serum apoB simultaneously [27]. Hence, the results of this study provided a possibility to reduce LM risk by using these...
drugs. On the other side, apoAI mimetic peptides could now be synthesized artificially, including D-4 F, L-4 F, L-5 F and Tg6F. These mimetics were found to reduce metastasis of colorectal cancer in animal models and expected to become new agents for managing LM [7]. Moreover, recombinant apoB could be used as a carrier of anti-tumor drugs, such as chemotherapy agents and small interfering RNA targeting oncogenes. It might be regarded as another therapeutic choice for LM from RC [15].

As far as we know, this study presented apoB-to-apoAI ratio as an independent predictor of LM from RC for the first time. The following advantages made its results quite reliable. First, this study analyzed a large cohort of 599 locally advanced RC patients. Second, the patients were treated uniformly with NACRT plus surgery, the current mainstream treatment. Third, all the patients were followed up for a sufficient time of 5 years. Fourth, as many known factors of RC were involved as possible for screening. Yet, selection biases might not completely be avoided in this study, due to its retrospective, single-institutional nature. So we suggested the results be validated in a prospective cohort, or a cohort from other institution.

Conclusions
Pretreatment level of serum apoB-to-apoAI ratio was associated negatively with the 5-year LMFS of locally advanced RC patients. It could be considered as a new predictive biomarker and potential therapeutic target for LM from RC.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 2 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 3 Department of Radiation Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 4 Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.

Received: 3 May 2021   Accepted: 7 December 2021

Published online: 03 January 2022

References
1. Petrelli F, Trevisan F, Cabiddu M, et al. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes. Ann Surg. 2020; 271(3): 440–448.
2. Huang WS, Kuan FC, Lin MH, Chen MF, Chen WC. Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer. Ann Surg Oncol. 2020; 27(11): 4309–4318.
3. Ishimaru K, Kawai K, Nozawa H, et al. Hazard function analysis of metastatic recurrence after colorectal cancer surgery-A nationwide retrospective study. J Surg Oncol. 2021; 124(4): 1015–1022.
4. Rumpold H, Kirchweger P, Niedersüß-Beke D, et al. Prognostic Value of metastatic pattern in colorectal cancer: a multicenter retrospective analysis in a real-life cohort. Acta Oncol. 2021; 60(2): 180–186.
5. Chen CH, Hsieh MC, Hsiao PK, Lin EK, Lu YJ, Wu SY. Tumor location is an independent predictive factor for distant metastasis and metastatic sites of rectal adenocarcinoma in patients receiving total mesorectal excision. J Cancer. 2018; 9(6): 950–958.
6. Meltzer S, Torgunrud A, Abrahamsson H, et al. The circulating soluble form of the CD40 cytokinematic immune checkpoint receptor and liver metastasis risk in rectal cancer. Br J Cancer. 2021 Apr 9. [Epub ahead of print]
7. Delk SC, Chattopadhyay A, Escola-Gil JC, Fogelman AM, Reddy ST. Apolipoprotein mimetics in cancer. Semin Cancer Biol. 2020 Nov 11. [Epub ahead of print]
8. Quan Q, Huang Y, Chen Q, et al. Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol. 2017; 10(2): 288–294.
9. Ye J, Luo QY, Wang XP, et al. Serum Apolipoprotein A-I Combined With C-Reactive Protein Serves As A Novel Prognostic Stratification System For Colorectal Cancer. Cancer Manag Res. 2019; 11: 9265–9276.
10. Chen XQ, Wu PW, Liu DH, Yan SJ, Shen XM, Yang LY. Prognostic significance of high triglyceride and apolipoprotein B levels in patients with stage III and high-risk stage II colorectal cancer undergoing curative surgery. Oncol Lett. 2020; 20(1): 705–714.
11. Yang DD, Chen ZH, Wang DS, et al. Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. J Cancer. 2020; 11(5): 1063–1074.
12. Chang H, Yu X, Chen K, et al. Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis. J Cancer. 2018; 9(23): 4346–4354.
13. Besurtt G, Damato A, Venturielli F, et al. Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients. BMC Cancer. 2021; 21(1): 253.
14. Vona R, lessi E, Matarese P. Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity? Front Cell Dev Biol. 2021; 9: 623908.
15. Di L, Mateiyeu A. Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential. Drug Deliv. 2021; 28(1): 408–421.
16. Zamanian-Daryoush M, DiDonato JA. Apolipoprotein A-I and Cancer. Front Pharmacol. 2015; 6: 265.
17. Cheng T, Dai X, Zhou DL, Lv Y, Miao LY. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Med Oncol. 2015; 32(1): 407.
18. Guo S, He X, Chen Q, et al. The Effect of Preoperative Apolipoprotein A-I on the Prognosis of Surgical Renal Cell Carcinoma: A Retrospective Large Sample Study. Medicine (Baltimore). 2016; 95(12): e3147.
19. Wang XP, Li XH, Zhang L, et al. High level of serum apolipoprotein A-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma. BMC Cancer. 2016; 16: 516.
20. Chang H, Wei JW, Chen K, et al. Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-modulated Radiotherapy. J Cancer. 2018; 9(4): 702–710.
21. Liu X, Wang Y, Qu H, et al. Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. Jpn J Clin Oncol. 2013; 43(4): 362–368.
22. Cedo L, Reddy ST, Mato E, Blanco-Vaca F, Escola-Gil JC. HDL and LDL Potential New Players in Breast Cancer Development. J Clin Med. 2019; 8(6): 853.
23. Guo SP, Chen C, Zeng ZF, et al. Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy. Cancer Manag Res. 2021; 13: 2623–2631.
24. Simio P, Väyrynen JP, Klintstrup K, et al. Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer. Sci Rep. 2017; 7(1): 5374.
25. Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N. Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia. J Clin Lipidol. 2015; 9(5): 709–715.
26. Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Effect of niacin on high-density lipoprotein apolipoprotein a-1 kinetics in statin-treated patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014; 34(2): 427–432.
27. Wang H, Li H, Zhou Y, Liu J, Wang F, Zhao Q. Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate. Curr Pharm Des. 2019; 25(44): 4725–4734.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions